Revumenib for people with myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a confirmed diagnosis of myelofibrosis (either primary or after ET/PV).
- You have intermediate-1 or higher risk disease (your doctor can confirm this).
- If you haven't been on a JAK inhibitor, you must have tried one and it didn't work or you couldn't tolerate it, OR you are not a candidate for one. OR you are already on a JAK inhibitor with stable dose for at least 12 weeks.
- You must have at least one sign of active disease: enlarged spleen (≥5 cm below ribs), symptoms score ≥10, or need for blood transfusions.
- Your organ function must be adequate (kidney, liver, heart) and your blood counts must meet certain levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.